vs
Apellis Pharmaceuticals, Inc.（APLS）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是BRC Group Holdings, Inc.的1.1倍（$199.9M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs -29.5%，领先77.4%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -21.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -15.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
APLS vs RILY — 直观对比
营收规模更大
APLS
是对方的1.1倍
$188.3M
营收增速更快
APLS
高出15.9%
-21.9%
净利率更高
RILY
高出77.4%
-29.5%
两年增速更快
APLS
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $188.3M |
| 净利润 | $-59.0M | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | -25.6% | 32.3% |
| 净利率 | -29.5% | 47.9% |
| 营收同比 | -5.9% | -21.9% |
| 净利润同比 | -62.2% | 1710.8% |
| 每股收益（稀释后） | $-0.40 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSRILY
| Q4 25 | $199.9M | $188.3M | ||
| Q3 25 | $458.6M | $215.3M | ||
| Q2 25 | $178.5M | $188.2M | ||
| Q1 25 | $166.8M | $197.2M | ||
| Q4 24 | $212.5M | $241.0M | ||
| Q3 24 | $196.8M | $225.5M | ||
| Q2 24 | $199.7M | $256.0M | ||
| Q1 24 | $172.3M | $263.4M |
净利润APLSRILY
| Q4 25 | $-59.0M | $90.3M | ||
| Q3 25 | $215.7M | $91.1M | ||
| Q2 25 | $-42.2M | $139.5M | ||
| Q1 25 | $-92.2M | $-10.0M | ||
| Q4 24 | $-36.4M | $-5.6M | ||
| Q3 24 | $-57.4M | $-284.4M | ||
| Q2 24 | $-37.7M | $-433.6M | ||
| Q1 24 | $-66.4M | $-49.2M |
毛利率APLSRILY
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率APLSRILY
| Q4 25 | -25.6% | 32.3% | ||
| Q3 25 | 48.7% | 30.4% | ||
| Q2 25 | -18.6% | 5.7% | ||
| Q1 25 | -50.0% | -31.2% | ||
| Q4 24 | -12.3% | -69.2% | ||
| Q3 24 | -24.0% | -36.4% | ||
| Q2 24 | -14.7% | -90.8% | ||
| Q1 24 | -36.0% | -6.1% |
净利率APLSRILY
| Q4 25 | -29.5% | 47.9% | ||
| Q3 25 | 47.0% | 42.3% | ||
| Q2 25 | -23.6% | 74.1% | ||
| Q1 25 | -55.3% | -5.1% | ||
| Q4 24 | -17.1% | -2.3% | ||
| Q3 24 | -29.2% | -126.1% | ||
| Q2 24 | -18.9% | -169.4% | ||
| Q1 24 | -38.5% | -18.7% |
每股收益（稀释后）APLSRILY
| Q4 25 | $-0.40 | $2.78 | ||
| Q3 25 | $1.67 | $2.91 | ||
| Q2 25 | $-0.33 | $4.50 | ||
| Q1 25 | $-0.74 | $-0.39 | ||
| Q4 24 | $-0.30 | $-0.01 | ||
| Q3 24 | $-0.46 | $-9.39 | ||
| Q2 24 | $-0.30 | $-14.35 | ||
| Q1 24 | $-0.54 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $370.1M | $-171.5M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSRILY
| Q4 25 | $466.2M | $226.6M | ||
| Q3 25 | $479.2M | $184.2M | ||
| Q2 25 | $370.0M | $267.4M | ||
| Q1 25 | $358.4M | $138.3M | ||
| Q4 24 | $411.3M | $146.9M | ||
| Q3 24 | $396.9M | $159.2M | ||
| Q2 24 | $360.1M | $236.9M | ||
| Q1 24 | $325.9M | $190.7M |
总债务APLSRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSRILY
| Q4 25 | $370.1M | $-171.5M | ||
| Q3 25 | $401.2M | $-260.5M | ||
| Q2 25 | $156.3M | $-351.7M | ||
| Q1 25 | $164.2M | $-496.8M | ||
| Q4 24 | $228.5M | $-488.2M | ||
| Q3 24 | $237.1M | $-497.6M | ||
| Q2 24 | $264.3M | $-218.3M | ||
| Q1 24 | $266.7M | $228.4M |
总资产APLSRILY
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $821.4M | $1.5B | ||
| Q1 25 | $807.3M | $1.5B | ||
| Q4 24 | $885.1M | $1.8B | ||
| Q3 24 | $901.9M | $2.2B | ||
| Q2 24 | $904.5M | $3.2B | ||
| Q1 24 | $831.9M | $5.0B |
负债/权益比APLSRILY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSRILY
| Q4 25 | $-14.2M | $26.2M | ||
| Q3 25 | $108.5M | $-60.6M | ||
| Q2 25 | $4.4M | $-25.6M | ||
| Q1 25 | $-53.4M | $184.0K | ||
| Q4 24 | $19.4M | $-2.7M | ||
| Q3 24 | $34.1M | $19.5M | ||
| Q2 24 | $-8.3M | $111.5M | ||
| Q1 24 | $-133.0M | $135.4M |
自由现金流APLSRILY
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSRILY
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSRILY
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | 0.50× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
